AbCellera Biologics Inc.
ABCL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1,503,342 | $1,023,885 | $663,855 | $866,568 |
| - Cash | $83,159 | $92,437 | $159,266 | $156,325 |
| + Debt | $137,052 | $142,080 | $67,847 | $65,364 |
| Enterprise Value | $1,557,235 | $1,073,528 | $572,436 | $775,607 |
| Revenue | $8,955 | $17,084 | $4,235 | $5,050 |
| % Growth | -47.6% | 303.4% | -16.1% | – |
| Gross Profit | $8,955 | $10,025 | $4,235 | $5,050 |
| % Margin | 100% | 58.7% | 100% | 100% |
| EBITDA | -$40,224 | -$38,833 | -$51,902 | -$55,311 |
| % Margin | -449.2% | -227.3% | -1,225.5% | -1,095.3% |
| Net Income | -$57,119 | -$34,727 | -$45,621 | -$34,210 |
| % Margin | -637.8% | -203.3% | -1,077.2% | -677.4% |
| EPS Diluted | -0.19 | -0.12 | -0.15 | -0.12 |
| % Growth | -58.3% | 20% | -25% | – |
| Operating Cash Flow | -$52,594 | -$32,404 | -$11,554 | -$8,000 |
| Capital Expenditures | -$8,928 | -$13,365 | -$10,636 | -$15,630 |
| Free Cash Flow | -$61,522 | -$45,769 | -$22,190 | -$23,630 |